Labcorp raises annual profit forecast on strong diagnostic testing demand

Labcorp (LH.N) raised its 2025 adjusted profit forecast to $16.05-$16.50 per share after exceeding second-quarter profit and revenue estimates, driven by robust demand for diagnostic tests. The company reported a 9.5% revenue increase to $3.53 billion and adjusted EPS of $4.35, attributing strength to underlying business performance and a weaker dollar. This strong performance, fueled by steady demand for non-urgent surgeries, reflects a positive trend also benefiting peers in the diagnostic and biopharma lab services sector.

Analysis

Labcorp (LH) reported significant operational strength in its second-quarter results, exceeding Wall Street estimates with a 9.5% year-over-year revenue increase to $3.53 billion against a $3.49 billion estimate, and an adjusted EPS of $4.35 versus a $4.17 consensus. This outperformance was driven by broad-based demand, evidenced by an 8.9% revenue growth in its core diagnostic lab business and an even stronger 11% growth in its biopharma laboratory services unit. Consequently, management raised its full-year 2025 adjusted profit forecast to a range of $16.05 to $16.50 per share, signaling strong confidence in sustained business momentum. The positive results are attributed to both fundamental business strength, buoyed by steady demand for non-urgent surgeries, and favorable macroeconomic conditions, specifically a weaker dollar. This trend appears to be sector-wide, as peer Quest Diagnostics also raised its forecast, suggesting a healthy market environment for diagnostic testing services.

Key Decisions for Investors

• Given the strong earnings beat and upwardly revised full-year guidance, investors should view this as a fundamentally positive signal for Labcorp's near-term outlook, supporting a bullish thesis.
• The report indicates a sector-wide tailwind, as peer Quest Diagnostics is also benefiting from similar demand drivers, suggesting that the diagnostic lab space as a whole warrants consideration for investment.
• Investors should monitor the sustainability of demand for non-urgent surgeries and any future shifts in currency exchange rates, as the company identified these as key drivers of the current outperformance.